NCT04772989 - A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 19, 2021

Primary Completion Date

August 25, 2025

Study Completion Date

August 25, 2025

Conditions

Advanced Solid TumorNon Small Cell Lung Cancer (NSCLC)MelanomaCervical CancerMultiple MyelomaLymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma (DLBCL)Gastric CancerGastroesophageal Junction AdenocarcinomaEsophageal Cancer

Interventions

DRUG

AB308

Administered intravenously (IV) as specified in the treatment arm

DRUG

Zimberelimab

Administered IV as specified in the treatment arm

Trial Locations (22)

15240

University of Pittsburgh Medical Center, Pittsburgh

32224

Mayo Clinic Jacksonville - PPDS, Jacksonville

37205

Tennessee Onocology - Nashville, Nashville

40202

Norton Cancer Insititute-Downtown, Louisville

43210

Ohio State University Comprehensive Cancer Center, Columbus

46526

Goshen Health System, Goshen

52242

Holden Comprehensive Cancer Center, Iowa City

53792

University of Wisconsin - Madison, Madison

55905

Mayo Clinic Rochester, Rochester

73104

University of Oklahoma Peggy and Charles Stephenson Cancer Center, Oklahoma City

78229

START South Texas Accelerated Research Therapeutics, San Antonio

84119

START South Texas Accelerated Research Therapeutics - Mountain Region, West Valley City

90095

UCLA Department of Medicine - Hematology/Oncology, Los Angeles

10032-3729

Columbia University Medical Center, New York

22033-1712

Virginia Cancer Specialists, Fairfax

Unknown

Specjalistyczna Praktyka Lekarska Slawomir Mandziuk, Lubin

Med-Polonia Sp. z o.o., Poznan

Hospital Universitario Vall d'Hebron, Barcelona

Clínica Universidad de Navarra - Madrid, Madrid

Hospital Universitario 12 de Octubre, Madrid

START MADRID Hospital Unviersitario Fundacion Jimenez Diaz, Madrid

Clínica Universidad de Navarra, Pamplona